Luis G Paz-Ares

Summary

Publications

  1. ncbi request reprint MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
    Sonia Molina-Pinelo
    Instituto de Biomedicina de Sevilla IBiS, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Manuel Siurot s n, 41013 Seville, Spain
    BMC Cancer 14:656. 2014
  2. pmc MicroRNA-dependent regulation of transcription in non-small cell lung cancer
    Sonia Molina-Pinelo
    Molecular Oncology and New Therapies Group Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    PLoS ONE 9:e90524. 2014
  3. pmc PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
    Purificacion Estevez-Garcia
    Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    BMC Cancer 12:514. 2012
  4. ncbi request reprint PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Servicio de Oncología Médica, University Hospital Virgen del Rocío, Seville, Spain
    J Clin Oncol 31:2895-902. 2013
  5. ncbi request reprint A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
    Luis Paz-Ares
    Department of Medical Oncology, IBIS and Hospital Universitario Virgen del Rocio CSIC Universidad de Sevilla, Servicio de Oncologia, Seville, Spain
    J Thorac Oncol 8:329-37. 2013
  6. ncbi request reprint Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Investigaciones Biomédicas de Sevilla, Avenida Manuel Siurot s n, Seville, Spain 41013
    J Clin Oncol 30:3084-92. 2012
  7. pmc Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advan
    Luis G Paz-Ares
    University Hospital Virgen del Rocio, Seville, Spain
    BMC Cancer 10:85. 2010
  8. pmc PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Lungen Clinic Großhansdorf, Großhansdorf, Germany Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocio, CSIC and Seville University, Seville, Spain San Camillo Forlanini Hospital, Rome, Italy Le Mans Regional Hospital, Le Mans, France Jawaharlal Nehru Cancer Hospital and Research Center, Bhopal, India University Medical Center Hamburg Eppendorf, Hamburg, Germany Eli Lilly and Company, Indianapolis, Indiana Eli Lilly and Company, Houten, The Netherlands and Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 9:205-13. 2014
  9. ncbi request reprint Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study
    Cesare Gridelli
    Division of Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy Department of Lung Diseases, San Camillo Hospital, Rome, Italy Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg TLRC H, Heidelberg, Germany Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India Centre Catherine De Sienne, Nantes, France Christie Hospital NHS Foundation Trust, Manchester, England CHR La Citadelle, Liege, Belgium Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France Eli Lilly and Company, Indianapolis, IN Eli Lilly and Company, Madrid, Spain Eli Lilly and Company, Neuilly sur Seine Cedex, France Eli Lilly and Company, Houten, The Netherlands and University Hospital, Virgen del Rocio, Seville, Spain
    J Thorac Oncol 9:991-7. 2014

Collaborators

Detail Information

Publications9

  1. ncbi request reprint MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
    Sonia Molina-Pinelo
    Instituto de Biomedicina de Sevilla IBiS, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Manuel Siurot s n, 41013 Seville, Spain
    BMC Cancer 14:656. 2014
    ..The aim of our study was to evaluate the ability of miRNA expression patterns to predict chemotherapy response in a cohort of 78 patients with metastatic CRC (mCRC)...
  2. pmc MicroRNA-dependent regulation of transcription in non-small cell lung cancer
    Sonia Molina-Pinelo
    Molecular Oncology and New Therapies Group Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    PLoS ONE 9:e90524. 2014
    ..These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies. ..
  3. pmc PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
    Purificacion Estevez-Garcia
    Instituto de Biomedicina de Sevilla IBIS HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain
    BMC Cancer 12:514. 2012
    ..VEGFR and PDGFR are key players involved in this process. The purpose of this study was to assess the incidence of genetic variants in these receptors and its potential clinical implications in colorectal cancer (CRC)...
  4. ncbi request reprint PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Servicio de Oncología Médica, University Hospital Virgen del Rocío, Seville, Spain
    J Clin Oncol 31:2895-902. 2013
    ..62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data...
  5. ncbi request reprint A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
    Luis Paz-Ares
    Department of Medical Oncology, IBIS and Hospital Universitario Virgen del Rocio CSIC Universidad de Sevilla, Servicio de Oncologia, Seville, Spain
    J Thorac Oncol 8:329-37. 2013
    ..This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC)...
  6. ncbi request reprint Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
    Luis G Paz-Ares
    Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Investigaciones Biomédicas de Sevilla, Avenida Manuel Siurot s n, Seville, Spain 41013
    J Clin Oncol 30:3084-92. 2012
    ..This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC)...
  7. pmc Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advan
    Luis G Paz-Ares
    University Hospital Virgen del Rocio, Seville, Spain
    BMC Cancer 10:85. 2010
    ....
  8. pmc PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Lungen Clinic Großhansdorf, Großhansdorf, Germany Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocio, CSIC and Seville University, Seville, Spain San Camillo Forlanini Hospital, Rome, Italy Le Mans Regional Hospital, Le Mans, France Jawaharlal Nehru Cancer Hospital and Research Center, Bhopal, India University Medical Center Hamburg Eppendorf, Hamburg, Germany Eli Lilly and Company, Indianapolis, Indiana Eli Lilly and Company, Houten, The Netherlands and Division of Medical Oncology, San Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 9:205-13. 2014
    ..62) and death (hazard ratio = 0.78) versus placebo in patients with advanced nonsquamous non-small-cell lung cancer. To further understand the survival data, descriptive subgroup analyses were undertaken...
  9. ncbi request reprint Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study
    Cesare Gridelli
    Division of Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy Department of Lung Diseases, San Camillo Hospital, Rome, Italy Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg TLRC H, Heidelberg, Germany Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India Centre Catherine De Sienne, Nantes, France Christie Hospital NHS Foundation Trust, Manchester, England CHR La Citadelle, Liege, Belgium Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France Eli Lilly and Company, Indianapolis, IN Eli Lilly and Company, Madrid, Spain Eli Lilly and Company, Neuilly sur Seine Cedex, France Eli Lilly and Company, Houten, The Netherlands and University Hospital, Virgen del Rocio, Seville, Spain
    J Thorac Oncol 9:991-7. 2014
    ..Here we report efficacy and safety results from the PARAMOUNT study for elderly (≥70 years) and non-elderly (<70 years) patients...